2023
Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review
Lozar T, Wang W, Gavrielatou N, Christensen L, Lambert P, Harari P, Rimm D, Burtness B, Kuhar C, Carchman E. Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review. Viruses 2023, 15: 2320. PMID: 38140561, PMCID: PMC10748233, DOI: 10.3390/v15122320.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaTriple-negative breast cancerCancer typesPredictive significancePrognostic factorsClinical outcomesPrognostic significanceCell carcinomaHuman cancersCervical squamous cell carcinomaNeck squamous cell carcinomaAvailable clinical evidenceCochrane Central RegisterInferior clinical outcomesPositive prognostic factorNegative predictive factorNegative prognostic factorWeb of ScienceCentral RegisterControlled TrialsCervical cancerClinical evidencePredictive factorsPancreatic cancerEligible studiesPaclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial
Stockton S, Catalano P, Cohen S, Burtness B, Mitchell E, Dotan E, Lubner S, Kumar P, Mulcahy M, Fisher G, Crandall T, Benson A. Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial. The Oncologist 2023, 28: 827-e822. PMID: 37104870, PMCID: PMC10485278, DOI: 10.1093/oncolo/oyad096.Peer-Reviewed Original ResearchConceptsProgression-free survivalSecond-line therapyGastroesophageal junction cancerArm AMetastatic esophagealJunction cancerArm BMedian progression-free survivalRandomized phase II trialMedian overall survivalObjective response rateSecond-line treatmentAdvanced esophageal cancerInsulin-like growth factor 1 receptorPhase II trialStandard of careGrowth factor 1 receptorFactor 1 receptorStable diseaseII trialMetastatic settingPrimary endpointOverall survivalPreclinical evidenceClinical outcomes
2019
Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy
LOGANADANE G, KANN BH, PARK HS, JOHNSON SB, MEHRA S, JUDSON BL, BHATIA A, BELKACEMI Y, YARBROUGH WG, BURTNESS B, HUSAIN ZA. Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy. Anticancer Research 2019, 39: 4885-4890. PMID: 31519591, DOI: 10.21873/anticanres.13674.Peer-Reviewed Original ResearchConceptsLocoregional recurrence-free survivalAdjuvant therapyNeck squamous cell carcinomaOutcomes of patientsRecurrence-free survivalSquamous cell carcinomaNeck cancer patientsHNSCC patientsClinical outcomesRecurrence rateCell carcinomaMean TTPCancer patientsPatientsTherapyResectionMonthsOutcomesHNSCCSurgeryCarcinomaHeadIncidenceProgression
2017
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
Cohen EEW, Licitra LF, Burtness B, Fayette J, Gauler T, Clement PM, Grau JJ, del Campo JM, Mailliez A, Haddad RI, Vermorken JB, Tahara M, Guigay J, Geoffrois L, Merlano MC, Dupuis N, Krämer N, Cong XJ, Gibson N, Solca F, Ehrnrooth E, Machiels J. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Annals Of Oncology 2017, 28: 2526-2532. PMID: 28961833, PMCID: PMC5834024, DOI: 10.1093/annonc/mdx344.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravenousAdministration, OralAfatinibAntimetabolites, AntineoplasticBiomarkers, TumorBiopsyCarcinoma, Squamous CellDisease-Free SurvivalHead and Neck NeoplasmsHumansMethotrexateNeoplasm MetastasisNeoplasm Recurrence, LocalPredictive Value of TestsQuinazolinesSquamous Cell Carcinoma of Head and NeckConceptsProgression-free survivalMetastatic headEfficacy outcomesMedian progression-free survivalRecurrent/metastatic headNeck squamous cell carcinomaTumor biomarkersNeck 1 trialP16-positive diseaseSecond-line afatinibOverall study populationSubset of patientsP16-negative tumorsSquamous cell carcinomaEnhanced clinical outcomesBiomarker analysisM HNSCCTherapy-naïveBaseline characteristicsStudy entryClinical outcomesHNSCC patientsPlatinum therapyCell carcinomaNeck cancerGenomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).
Haddad R, Seiwert T, Chow L, Gupta S, Weiss J, Gluck I, Eder J, Burtness B, Tahara M, Keam B, Kang H, Muro K, Albright A, Huang L, Ayers M, Mogg R, Cristescu R, Cheng J, Mehra R. Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2017, 35: 6009-6009. DOI: 10.1200/jco.2017.35.15_suppl.6009.Peer-Reviewed Original ResearchNeoantigen loadWhole-exome sequencingPD-1/EBV statusObjective responseGene expression profilesNeck squamous cell carcinomaAnti CTLA-4PD-1 therapyIndependent predictive valueSquamous cell carcinomaCentral immune toleranceMutational loadFFPE tumor specimensSomatic mutational loadGEP scoreL1 immunotherapyL1 therapyClinical outcomesImmune toleranceSelect tumorsCell carcinomaCTLA-4Combined cohortViral status
2016
Tumor Biomarker Association With Clinical Outcomes in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Patients (Pts) Treated With Afatinib Versus Methotrexate (MTX): LUX-Head & Neck 1 (LHN1)
Cohen E, Licitra L, Burtness B, Fayette J, Gauler T, Clement P, Grau J, del Campo J, Mailliez A, Haddad R, Vermorken J, Tahara M, Guigay J, Geoffrois L, Merlano M, Cong X, Gibson N, Solca F, Ehrnrooth E, Machiels J. Tumor Biomarker Association With Clinical Outcomes in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Patients (Pts) Treated With Afatinib Versus Methotrexate (MTX): LUX-Head & Neck 1 (LHN1). International Journal Of Radiation Oncology • Biology • Physics 2016, 94: 868-869. DOI: 10.1016/j.ijrobp.2015.12.032.Peer-Reviewed Original Research
2014
Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials
Argiris A, Li S, Ghebremichael M, Egloff AM, Wang L, Forastiere AA, Burtness B, Mehra R. Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials. Annals Of Oncology 2014, 25: 1410-1416. PMID: 24799460, PMCID: PMC4071756, DOI: 10.1093/annonc/mdu167.Peer-Reviewed Original ResearchConceptsProgression-free survivalHuman papillomavirusOverall survivalMetastatic SCCHNClinical outcomesClinical trialsEastern Cooperative Oncology Group trialMetastatic squamous cell carcinomaP16-negative patientsP16-positive patientsHPV-negative patientsObjective response ratePhase II trialPhase III trialsFavorable prognostic factorSquamous cell carcinomaUnfavorable risk factorsWide spectrum probeII trialMetastatic headHazard ratioIII trialsMedian survivalObjective responseHPV DNA
2013
Analysis of HPV and ERCC1 in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Mehra R, Egloff A, Li S, Yang D, Wang L, Zhu F, Forastiere A, Burtness B, Argiris A. Analysis of HPV and ERCC1 in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Journal Of Clinical Oncology 2013, 31: 6006-6006. DOI: 10.1200/jco.2013.31.15_suppl.6006.Peer-Reviewed Original ResearchCisplatin/paclitaxelHazard ratioHuman papillomavirusCisplatin/5-FUResponse rateM SCCHNOdds ratioExact testAnalysis of HPVMetastatic squamous cell carcinomaDocetaxel/irinotecanTumor p16 statusObjective response ratePhase II trialSquamous cell carcinomaCox regression modelLog-rank testPotential confounding factorsFisher's exact testHPV-/p16Better OSII trialHPV DNAClinical outcomesCell carcinomaAssociation of the 3'-untranslated region KRAS-variant with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Weidhaas J, Lee J, Slebos R, Howard J, Perez J, Gilbert J, Nallur S, Paranjape T, Garcia J, Burtness B, Forastiere A, Chung C. Association of the 3'-untranslated region KRAS-variant with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Journal Of Clinical Oncology 2013, 31: 6016-6016. DOI: 10.1200/jco.2013.31.15_suppl.6016.Peer-Reviewed Original ResearchNeck squamous cell carcinomaSquamous cell carcinomaKRAS-variantMetastatic headCell carcinomaP16/HPV statusRecurrent/metastatic headPoor progression-free survivalCisplatin resistanceHuman papillomavirus (HPV) statusProgression-free survivalTG/GGM HNSCCTumor DNA samplesHPV statusPatient demographicsHNSCC patientsClinical outcomesPoor outcomePoor prognosisPrognostic significancePredictive biomarkersClinical trialsProspective validationPromising biomarker
2010
SU‐GG‐T‐180: Intensity‐Modulated Radiation Therapy (IMRT) for the Para‐Nasal Sinus (PNS) Malignancies: Outcomes from Fox Chase Cancer Center (FCCC)
Turaka A, Cattaneo R, Nicos N, Lango M, Burtness B, Ridge J, Feigenberg S. SU‐GG‐T‐180: Intensity‐Modulated Radiation Therapy (IMRT) for the Para‐Nasal Sinus (PNS) Malignancies: Outcomes from Fox Chase Cancer Center (FCCC). Medical Physics 2010, 37: 3226-3226. DOI: 10.1118/1.3468570.Peer-Reviewed Original ResearchFox Chase Cancer CenterIntensity-modulated radiation therapySquamous cellsStage III/IV diseaseMedian age 68 yearsStage I/IILocoregional control rateAge 68 yearsOverall survival rateParanasal sinus tumorsBase of skullMedian followMedian doseLocal recurrenceMucosal melanomaSinus malignanciesClinical outcomesDistant metastasisNeck diseasePerineural invasionSinus tumorClinical stageHigher complicationsNegative marginsOptic apparatusUse of a Conventional Low Neck Field (LNF) and Intensity-Modulated Radiotherapy (IMRT): No Clinical Detriment of IMRT to an Anterior LNF During the Treatment of Head-and Neck-Cancer
Turaka A, Li T, Nicolaou N, Lango MN, Burtness B, Horwitz EM, Ridge JA, Feigenberg SJ. Use of a Conventional Low Neck Field (LNF) and Intensity-Modulated Radiotherapy (IMRT): No Clinical Detriment of IMRT to an Anterior LNF During the Treatment of Head-and Neck-Cancer. International Journal Of Radiation Oncology • Biology • Physics 2010, 79: 65-70. PMID: 20385457, PMCID: PMC3339153, DOI: 10.1016/j.ijrobp.2009.10.034.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Squamous CellChi-Square DistributionCombined Modality TherapyDisease-Free SurvivalFemaleFollow-Up StudiesGastrostomyHead and Neck NeoplasmsHumansLinear ModelsLymph Node ExcisionMaleMiddle AgedRadiotherapy DosageRadiotherapy, Intensity-ModulatedRetrospective StudiesTreatment FailureConceptsIntensity-modulated radiotherapyLow-neck fieldLower neckDisease-free survival ratesPercutaneous endoscopic gastrostomy tubeNeck fieldSingle-institution studySquamous cell carcinomaLog-rank testTreatment of headAnterior photon fieldAnterior low-neck fieldClinical detrimentCurative intentMedian ageClinical outcomesGastrostomy tubeNeck diseasePEG tubeCell carcinomaNeck cancerPhysician preferenceRegional failureStage IIIPatients
2009
Targeting EGFR resistance networks in head and neck cancer
Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS. Targeting EGFR resistance networks in head and neck cancer. Cellular Signalling 2009, 21: 1255-1268. PMID: 19258037, PMCID: PMC2770888, DOI: 10.1016/j.cellsig.2009.02.021.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaResponse of patientsPersonalized treatment approachesTumor progenitor cellsTypes of cancerAntibody agentsClinical outcomesCell carcinomaNeck cancerTreatment modalitiesInflammatory agentsTherapeutic strategiesTreatment approachesViral infectionEGFR/ErbB1Individual tumorsCancer typesProgenitor cellsCancerEGFREpigenetic modulationSurvival responseBiological featuresDevelopmental lineageOncoprotein
2007
Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer
Yu Z, Weinberger PM, Sasaki C, Egleston BL, Speier WF, Haffty B, Kowalski D, Camp R, Rimm D, Vairaktaris E, Burtness B, Psyrri A. Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer. Cancer Epidemiology Biomarkers & Prevention 2007, 16: 553-558. PMID: 17372251, DOI: 10.1158/1055-9965.epi-06-0121.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCarcinoma, Squamous CellChi-Square DistributionFemaleHumansImmunoenzyme TechniquesMaleMiddle AgedNeoplasm Recurrence, LocalOropharyngeal NeoplasmsPhosphorylationPredictive Value of TestsPrognosisProportional Hazards ModelsProtein Array AnalysisProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseSurvival AnalysisConceptsNuclear p-AktAkt activationP-AktOropharyngeal squamous cell cancerSquamous cell carcinoma progressionPhosphorylated AktCohort of patientsLocal recurrence rateOverall survival rateSquamous cell cancerPoor clinical outcomeAdverse patient outcomesP-AKT levelsPromising molecular targetP-AKT expressionProtein expression levelsPhosphorylation of AktDisease recurrenceLocal recurrenceCell cancerClinical outcomesAdjusted analysisPrognostic significanceRecurrence ratePatient outcomes